Patents by Inventor A. Bennett Jenson
A. Bennett Jenson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230049732Abstract: Some embodiments of the invention include virus-like particle (VLP) binding agents, and related polynucleotides, cells, methods of making, and compositions. Other embodiments of the invention include methods of detecting VLPs, parvovirus, erythrovirus or parvovirus B19 using a VLP binding agent and diagnostic methods for parvovirus, erythrovirus or parvovirus B19. Further embodiments include methods for administering VLP binding agents to an animal. Other embodiments include treating parvovirus, erythrovirus or parvovirus B19 infections and other diseases. Additional embodiments of the invention are also discussed.Type: ApplicationFiled: December 30, 2020Publication date: February 16, 2023Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Shin-je GHIM, A. Bennett JENSON, Maryam ZAHIN
-
Publication number: 20210292372Abstract: Some embodiments of the invention include inventive polypeptides (e.g., mutant VP2 proteins) and virus-like particles made from the inventive polypeptides. Other embodiments of the invention include compositions for treating (e.g., preventing) parvovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Further embodiments include methods for administering compositions to an animal. Other embodiments include treating (e.g., preventing) parvovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Still other embodiments include nucleic acid sequences that encode the inventive polypeptides. Additional embodiments of the invention are also discussed.Type: ApplicationFiled: April 14, 2021Publication date: September 23, 2021Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Shin-je GHIM, A. Bennett JENSON, John O. TRENT
-
Patent number: 11008367Abstract: Some embodiments of the invention include inventive polypeptides (e.g., mutant VP2 proteins) and virus-like particles made from the inventive polypeptides. Other embodiments of the invention include compositions for treating (e.g., preventing) parvovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Further embodiments include methods for administering compositions to an animal. Other embodiments include treating (e.g., preventing) parvovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Still other embodiments include nucleic acid sequences that encode the inventive polypeptides. Additional embodiments of the invention are also discussed.Type: GrantFiled: December 27, 2018Date of Patent: May 18, 2021Assignee: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Shin-je Ghim, A. Bennett Jenson, John O. Trent
-
Publication number: 20190202867Abstract: Some embodiments of the invention include inventive polypeptides (e.g., mutant VP2 proteins) and virus-like particles made from the inventive polypeptides. Other embodiments of the invention include compositions for treating (e.g., preventing) parvovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Further embodiments include methods for administering compositions to an animal. Other embodiments include treating (e.g., preventing) parvovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Still other embodiments include nucleic acid sequences that encode the inventive polypeptides. Additional embodiments of the invention are also discussed.Type: ApplicationFiled: December 27, 2018Publication date: July 4, 2019Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Shin-je Ghim, A. Bennett Jenson, John O. Trent
-
Patent number: 10214565Abstract: Some embodiments of the invention include inventive polypeptides (e.g., mutant VP2 proteins) and virus-like particles made from the inventive polypeptides. Other embodiments of the invention include compositions for treating (e.g., preventing) parvovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Further embodiments include methods for administering compositions to an animal. Other embodiments include treating (e.g., preventing) parvovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Still other embodiments include nucleic acid sequences that encode the inventive polypeptides. Additional embodiments of the invention are also discussed.Type: GrantFiled: March 10, 2015Date of Patent: February 26, 2019Assignee: University of Louisville Research Foundation, Inc.Inventors: Shin-je Ghim, A. Bennett Jenson, John O. Trent
-
Publication number: 20170015712Abstract: Some embodiments of the invention include inventive polypeptides (e.g., mutant VP2 proteins) and virus-like particles made from the inventive polypeptides. Other embodiments of the invention include compositions for treating (e.g., preventing) parvovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Further embodiments include methods for administering compositions to an animal. Other embodiments include treating (e.g., preventing) par vovirus (e.g., erythrovirus or parvovirus B19) infection and other diseases. Still other embodiments include nucleic acid sequences that encode the inventive polypeptides. Additional embodiments of the invention are also discussed.Type: ApplicationFiled: March 10, 2015Publication date: January 19, 2017Applicant: University of Louisville Research Foundation, Inc.Inventors: Shin-je Ghim, A. Bennett Jenson, John O. Trent
-
Publication number: 20130295125Abstract: Methods and compositions for detecting MusPV, also known as MmuPv1, infection of a rodent subject are described according to aspects of the present invention. In specific aspects, the present invention relates to assays for detecting MusPV infection of a rodent subject; vaccine compositions for inducing an immunological response against MusPV in a rodent subject; methods of inducing an immunological response to MusPV in a rodent subject; isolated MusPV protein; isolated antibodies which specifically binds to an MusPV protein, a fragment or variant thereof; isolated recombinantly expressed MusPV proteins; expression constructs comprising a nucleic acid encoding an MusPV protein; host cells comprising the expression construct; and hybridoma cell lines expressing an anti-MusPV monoclonal antibody specific for MusPV.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Applicants: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, THE JACKSON LABORATORYInventors: John P. Sundberg, Joongho Joh, A. Bennett Jenson, Shin-Je Ghim
-
Publication number: 20130295553Abstract: Methods and compositions for detecting MusPV, also known as MmuPv1, infection of a rodent subject are described according to aspects of the present invention. In specific aspects, the present invention relates to assays for detecting MusPV infection of a rodent subject; vaccine compositions for inducing an immunological response against MusPV in a rodent subject; methods of inducing an immunological response to MusPV in a rodent subject; isolated MusPV protein; isolated antibodies which specifically binds to an MusPV protein, a fragment or variant thereof; isolated recombinantly expressed MusPV proteins; expression constructs comprising a nucleic acid encoding an MusPV protein; host cells comprising the expression construct; and hybridoma cell lines expressing an anti-MusPV monoclonal antibody specific for MusPV.Type: ApplicationFiled: March 13, 2013Publication date: November 7, 2013Applicants: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, THE JACKSON LABORATORYInventors: John P. Sundberg, Joongho Joh, A. Bennett Jenson, Shin-Je Ghim
-
Publication number: 20110301860Abstract: Disclosed herein in various embodiments are systems and methods for categorizing biological fluids obtained from subjects into one or more disease or treatment categories. Embodiments of the systems and methods may transform easily obtainable body fluids such as blood, plasma, spinal fluid, and other fluids into signature differential scanning calorimetry (DSC) thermograms that may be used to distinguish a positive or negative correlation with a specific inflammatory disease, such as an autoimmune disease. Also disclosed are methods of detecting, diagnosing, and/or monitoring an inflammatory disease in a subject.Type: ApplicationFiled: June 9, 2011Publication date: December 8, 2011Applicants: LOUISVILLE BIOSCIENCE, INC., UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Jonathan B. Chaires, Nichola C. Garbett, A. Bennett Jenson, Albert S. Benight, Greg P. Brewood, Daniel J. Fish
-
Patent number: 8012679Abstract: Seven polyclonal and monoclonal antibodies were characterized for their ability to react specifically with either conformational or non-conformational epitopes of the HPV-1 virion. Using these antibodies, it was shown that the HPV-1 L1 protein (when expressed by an SV40 vector in cos cells) displayed conformational epitopes characteristic of intact viral particles. In addition, the L1 capsid protein was translocated normally into cell nuclei, was of appropriate size (57kD), and could be isolated in native form by immunoprecipitation techniques. Most importantly, the screening of expressed papillomavirus capsid proteins for reactivity with conformation-dependent antibodies represents a new, general methodology for ensuring that such proteins will be suitable for use in vaccine development or in the serologic detection/typing of human papillomavirus infections.Type: GrantFiled: December 16, 1996Date of Patent: September 6, 2011Assignee: Georgetown UniversityInventors: C. Richard Schlegel, A. Bennett Jenson
-
Publication number: 20100317567Abstract: Compositions for conferring protection against Equus caballus papillomavirus (EcPV) and Bovine papillomavirus (BPV) infection in a subject are provided and include a virus-like particle assembled from an EcPV L1 protein and virus like particle assembled from a BPV L1 protein. Methods for protecting a subject against EcPV and BPV infection are further provided and include administering to the subject a composition comprised of a virus-like particle assembled from an EcPV L1 protein and virus like particle assembled from a BPV L1 protein. Methods of diagnosing EcPV and/or BPV infection in a subject are also provided and include providing a virus-like particle assembled from a papillomavirus L1 protein selected from an EcPV L1 protein and a BPV L1 protein; contacting the virus-like particle with serum from the subject; and identifying the subject as having an infection if an antibody capable of binding the virus-like particle is detected in the serum.Type: ApplicationFiled: August 23, 2010Publication date: December 16, 2010Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: A. Bennett Jenson, Shin-je Ghim, Victoria B. Kyle, Joongho Joh
-
Publication number: 20100221280Abstract: Compositions for treating papillomavirus (PV) infection in a subject include a PV L2 polypeptide produced from a eukaryotic expression system.Type: ApplicationFiled: April 21, 2010Publication date: September 2, 2010Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Shin-je Ghim, A. Bennett Jenson, Amanda B. Lasnik, Donald M. Miller, Kenneth Palmer, Mark L. Smith
-
Publication number: 20090011996Abstract: Compositions for conferring protection against Equus caballus papillomavirus (EcPV) and Bovine papillomavirus (BPV) infection in a subject are provided and include a virus-like particle assembled from an EcPV L1 protein and virus like particle assembled from a BPV L1 protein. Methods for protecting a subject against EcPV and BPV infection are further provided and include administering to the subject a composition comprised of a virus-like particle assembled from an EcPV L1 protein and virus like particle assembled from a BPV L1 protein. Methods of diagnosing EcPV and/or BPV infection in a subject are also provided and include providing a virus-like particle assembled from a papillomavirus L1 protein selected from an EcPV L1 protein and a BPV L1 protein; contacting the virus-like particle with serum from the subject; and identifying the subject as having an infection if an antibody capable of binding the virus-like particle is detected in the serum.Type: ApplicationFiled: July 3, 2008Publication date: January 8, 2009Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: A. Bennett Jenson, Shin-je Ghim, Victoria B. Kyle, Joongho Joh
-
Patent number: 7445786Abstract: Composition for conferring protection against Tursiops truncatus papillomavirus (TtPV) infection in a subject includes a virus-like particle assembled from at least one type of TtPV L1 protein. Methods for protecting a subject against TtPV infection include administering to the subject an immunogenic composition including a virus-like particle assembled from at least one type of TtPV L1 protein. Methods for diagnosing TtPV infection in a subject include providing a virus-like particle assembled from at least one TtPV L1 protein; contacting the virus-like particle with serum obtained from the subject; and identifying the subject as having TtPV infection if a TtPV antibody capable of binding the virus-like particle is detected in the serum.Type: GrantFiled: April 10, 2007Date of Patent: November 4, 2008Inventors: Manuela Rehtanz, A. Bennett Jenson, Shin-je Ghim, Gregory D. Bossart
-
Publication number: 20080172184Abstract: A method of diagnosing or monitoring a condition of interest in a subject includes comparing thermograms generated using differential scanning calorimetery. A signature thermogram contains a protein composition pattern for a sample obtained from the subject. The signature thermogram is compared to a standard thermogram. Standard thermograms can include a negative standard thermogram containing a protein composition pattern associated with an absence of the condition of interest, and a positive standard thermogram containing a protein composition pattern associated with a presence of the condition of interest.Type: ApplicationFiled: January 11, 2008Publication date: July 17, 2008Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Jonathan B. Chaires, Nichola C. Garbett, A. Bennett Jenson
-
Publication number: 20080160040Abstract: Compositions for treating papillomavirus (PV) infection in a subject include a PV L2 polypeptide produced from a eukaryotic expression system.Type: ApplicationFiled: February 8, 2008Publication date: July 3, 2008Inventors: Shin-je Ghim, A. Bennett Jenson, Amanda B. Lasnik, Donald M. Miller, Kenneth Palmer, Mark L. Smith
-
Patent number: 6887478Abstract: Recombinantly produced L1 major capsid proteins which mimic conformational naturalizing epitopes on human and animal papilloma virions including canine and equine papilloma virions are provided. These recombinant proteins are useful as vaccines for conferring protection against papillomavirus infection. Antibodies to the recombinant protein are also provided. Such antibodies are useful in the diagnosis and treatment of viral infection.Type: GrantFiled: September 22, 2003Date of Patent: May 3, 2005Assignee: Georgetown UniversityInventors: C. Richard Schlegel, A. Bennett Jenson, Shin-je Ghim
-
Publication number: 20040086527Abstract: Recombinantly produced L1 major capsid proteins which mimic conformational naturalizing epitopes on human and animal papilloma virions including canine and equine papilloma virions are provided. These recombinant proteins are useful as vaccines for conferring protection against papillomavirus infection. Antibodies to the recombinant protein are also provided. Such antibodies are useful in the diagnosis and treatment of viral infection.Type: ApplicationFiled: September 22, 2003Publication date: May 6, 2004Inventors: C. Richard Schlegel, A. Bennett Jenson, Shin-Je Ghim
-
Publication number: 20020197264Abstract: Recombinantly produced LI major capsid proteins which mimic conformational naturalizing epitopes on human and animal papilloma virions including canine and equine papilloma virions are provided. These recombinant proteins are useful as vaccines for conferring protection against papillomavirus infection. Antibodies to the recombinant protein are also provided. Such antibodies are useful in the diagnosis and treatment of viral infection.Type: ApplicationFiled: April 2, 2001Publication date: December 26, 2002Applicant: Georgetown University School of MedicineInventors: C. Richard Schlegel, A. Bennett Jenson, Shin-Je Ghim
-
Patent number: 6485728Abstract: Recombinantly produced L1 major capsid proteins which mimic conformational naturalizing epitopes on human and animal papilloma virions including canine and equine papilloma virions are provided. These recombinant proteins are useful as vaccines for conferring protection against papillomavirus infection. Antibodies to the recombinant protein are also provided. such antibodies are useful in the diagnosis and treatment of viral infection.Type: GrantFiled: August 14, 1998Date of Patent: November 26, 2002Assignee: Georgetown University School of MedicineInventors: C. Richard Schlegel, A. Bennett Jenson, Shin-je Ghim